Paliperidone use in the elderly

Current Drug Safety

Volumn 5, Issue 2, 2010, Pages 149-152

  Madhusoodanan, Subramoniam ^a,b   Zaveri, Deval ^a,b  

^a ST JOHN S EPISCOPAL HOSPITAL   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

Elderly; Paliperidone; Use

Indexed keywords

OLANZAPINE; PALIPERIDONE; RISPERIDONE;

AGGRESSION; AKATHISIA; ARTICLE; ASTHENIA; ATRIOVENTRICULAR BLOCK; BIPOLAR DISORDER; CLINICAL TRIAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIZZINESS; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DYSTONIA; ELDERLY CARE; EXTRAPYRAMIDAL SYNDROME; FATIGUE; HAMILTON SCALE; HEADACHE; HEART BUNDLE BRANCH BLOCK; HUMAN; HYPERKINESIA; HYPERPROLACTINEMIA; HYPERSALIVATION; INSOMNIA; MAINTENANCE THERAPY; MANIA; MIXED MANIA AND DEPRESSION; MUSCLE HYPERTONIA; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SINUS ARRHYTHMIA; SOMNOLENCE; TACHYCARDIA; TREMOR; UPPER ABDOMINAL PAIN; XEROSTOMIA; YOUNG MANIA RATING SCALE;

EID: 77950816832     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488610790936132     Document Type: Article

References (31)

1. US Food and Drug Administration. FDA public advisory: deaths with antipsychotic in elderly patients with behavioral disturbances (online). Available from URL: http://www.fdaov/cder/drug/advisory/antipsychotics.htm
2. Invega™ Product information Janssen, LP, Titusville, NJ 08500. 2006.
3. Karlsson P, Dencker E, Mannaert E. Pharmacokinetics, dopamine D2 and serotonin 5-HT2A receptor occupancy and safety profile of paliperidone extended-release in healthy subjects. Schizophr Res 2006; 81(1): 85-86
4. Kane J, Canas F, Kramer M, et al. Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial. Schizophr Res 2007; 90: 147-161
5. Davidson M, Emsley R, Kramer M. Efficacy, safety and effect on functioning of paliperidone extended-release tablets in schizophrenia: An international 6-week placebo-controlled study. Schizophr Res 2006; 81(1): 43.
6. Marder SR, Kramer M, Ford L, et al. Efficacy and tolerability of two fixed dosages of paliperidone extended-release tablets in the treatment of acute schizophrenia: A 6-week placebo-controlled study. Schizophr Res 2006; 81(1): 56.
7. Vermeir M, Boom S, Naessens I, et al. Absorption, metabolism and excretion of a single oral dose of 14C-paliperidone 1 mg in healthy subjects. Clin Pharmacol Ther 2006; 79: 80.
8. Personal communication. Medical communications. Orthro-McNeil Janssen Scientific Affair LLC, Titusville NJ, Oct 9, 2007.
9. Canuso C, Lindenmayer JP, Carothers J, Kosik-Gonzalez C, Turkoz I, Schooler N. Randomized, double-blind, placebocontrolled study of flexible-dose paliperidone ER in the treatment of patients with schizoaffective disorder. Biol Psychiatry 2009; 65: 213S.
10. Canuso C, Lindenmayer JP, Carothers J, Kosik-Gonzalez C, Turkoz I, Schooler N. Randomized, double-blind, placebocontrolled study of two dose ranges of paliperidone ER in the treatment of subjects with schizoaffective disorder. Biol Psychiatry 2009; 65: 213-4S
11. Vieta E, Berwaerts I, Nuamah P, et al. Randomized, placebo, active controlled study of paliperidone ER for acute manic and mixed episodes in bipolar I disorder. Eur Neuropsychopharmacol 2008; 18(4): 369.
12. Corena-McLeod MP, Oliveros A, Charlesworth C, et al. Paliperidone as a mood stabilizer: a pre- frontal cortex synaptoneurosomal proteomics comparison with lithium and valproic acid after chronic treatment reveals similarities in protein expression. Brain Res 2008; 1233: 8-19.
13. US Food and Drug Administration-drugs safety and regulation, July 2009. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/appletter/ 2009/021999s013,s014ltr.pdf
14. Hough D. Paliperidone palmitate in prevention of symptom recurrence in patients with schizophrenia: a randomized doubleblind, placebo controlled study. Abstract NR4-029, presented at the American Psychiatric Association annual meeting May 6, 2008.
15. US Food and Drug Administration- drugs safety and regulation, July 2009. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/appletter/ 2009/022264s000ltr.pdf
16. Kramer M, Simpson G, Maciulis V, et al. Paliperidone extendedrelease tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2007: 27: 6-14.
17. Emsley R, Berwaets J, Eerdeken M, et al. Efficacy and safety of oral pailiperidone ER in treatment of acute schizophrenia: pooled data from three 52-week open-label studies. Int Clin Psychopharmacol 2008; 23: 343-356
18. David SR, Taylor CC, Kinon BJ, Breier A. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther 2002; 22: 1085-1096
19. Haddad PM, Wieck A. Antipsychotic induced hyperprolactinemia: mechanisms, clinical features and management. Drugs 2004; 64: 2291-2314
20. Young RM, Lawford BR, Barnes M. Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele. Br J Psychol 2004; 185: 147-151
21. Montgomery J, Winterbottom E, Jessani M, et al. Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment. J Clin Psychiatry 2004; 65: 1491-1498
22. Melkerson K. Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite. Hum Psychopharmacol Clin Exp 2006; 21: 529-532
23. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-276
24. Hedlug JL, Viewveg BW. The hamilton rating scale for depression. J Operat Psychiatry 1979; 10: 149-165
25. Young RC, Biggs JT, Ziegler VE, Meyer DA. Young Mania Rating Scale. In: Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association; 2000; pp. 540-542
26. Tzimos A, Samokhvalov V, Kramer M, et al. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension. Am J Geriatr Psychiatry 2008; 16: 31-43.
27. Madhusoodanan S, Brenner S, Adler D, et al. Use of Paliperidone in elderly patients with schizophrenia and schizoaffective disorder -a prosprective open label short term pilot study. Unpublished data.
28. Clinical Global Impressions, in ECDEU Assessment for psychopharmacology. Edited by Guy W. Rockville, MD, National Institute of Mental Health, 1976: pp. 217-222
29. Montgomery SA, Asberg MA. New depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-389
30. Chouinard G, Ross-Chouinard A, Annabel L, et al. The Extrapyramidal symptom Rating Scale (abstract). Can J Neurol Sci 1980: 7-233.
31. Ray W, Chung CP, Stern MC, et al. Atypical psychotropics and risk of sudden cardiac death. N Engl J Med 2009; 360: 225-235